3Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The HOPE Study Investigators[J]. N Engl J Med,2000,342(3) :145-153.
4Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension [J]. Lancet,1979,8121(313) :861-865.
5Cmickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure[J]. Lancent, 1987, 8533 (329) : 581-584.
6Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: dose a J-shaped curve exist in smokers[J]. Hypertens, 2003,21 (4) : 797-804.
7Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmis artan alone and in combination with ramipril global endpoint trial study[J].J Hypertens,2009,27(7):1360-1369.
8李勇.降压治疗是否越低越好 降压治疗存在J点.中华高血压杂志,2010,.
9Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT)Trial[J]. Eur Heart J,2010,31(23) :2897-2908.
10NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events[J]. New Engl J Med, 2010, 362(16) : 1533-1555.
